iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies. The company’s research centers on targeting key components of the tumor microenvironment to restore and enhance anti-tumor immune responses. Its core therapeutic approach involves small molecules and monoclonal antibodies designed to inhibit immunosuppressive pathways that allow cancers to evade immune surveillance.
The company’s pipeline includes EOS-850, an orally administered adenosine A2A receptor antagonist, and EOS-448, a first-in-class anti-TIGIT monoclonal antibody. EOS-850 is being evaluated as both a monotherapy and in combination with established immune checkpoint inhibitors in multiple tumor types. EOS-448 is under investigation for its potential to block the TIGIT pathway, thereby reinvigorating T-cell activity against solid tumors. iTeos also continues to advance additional preclinical programs targeting adenosine generation and TGF-β signaling.
Founded in 2015 as a spin-out from leading academic research institutions, iTeos Therapeutics completed its initial public offering on the NASDAQ in 2019. The company is headquartered in Cambridge, Massachusetts, with research and development laboratories in Gosselies, Belgium, supporting both early-stage discovery and global clinical trial activities. This transatlantic footprint enables iTeos to collaborate with academic centers and industry partners across North America and Europe.
iTeos is led by a management team with deep expertise in oncology drug development and regulatory strategy. The leadership group has navigated multiple clinical milestones, forging partnerships and securing funding to advance its immuno-modulatory candidates through regulatory interactions and patient trials. With a focus on translating scientific insights into differentiated therapies, the company aims to address high-unmet medical needs for patients with advanced cancers.
AI Generated. May Contain Errors.
